Century Therapeutics (IPSC) Interest & Investment Income (2022 - 2026)

Century Therapeutics (IPSC) has 5 years of Interest & Investment Income data on file, last reported at $2.0 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 16.64% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 43.04% decrease from a year earlier, with the FY2025 full-year figure at $7.3 million, down 43.52% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.0 million, up from $1.3 million in the prior quarter.
• Over the last five years, Interest & Investment Income for IPSC reached as high as $3.6 million in Q2 2024 and fell as low as $706000.0 in Q2 2022.
• Historically, Interest & Investment Income has averaged $2.5 million across 5 years, with a median of $2.6 million in 2023.
• Across the five-year window, Interest & Investment Income jumped 333.14% in 2023 and sank 54.56% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $1.4 million in 2022, then surged by 148.76% to $3.5 million in 2023, then retreated by 17.92% to $2.9 million in 2024, then sank by 54.56% to $1.3 million in 2025, then surged by 54.24% to $2.0 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $2.0 million in Q1 2026, $1.3 million in Q4 2025, and $1.6 million in Q3 2025.